AstraZeneca PE Ratio 2010-2023 | AZN
Current and historical p/e ratio for AstraZeneca (AZN) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AstraZeneca PE ratio as of April 26, 2024 is 20.26.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| AstraZeneca PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-04-26 |
75.17 |
|
39.15 |
| 2023-12-31 |
66.33 |
$1.92 |
34.55 |
| 2023-09-30 |
66.70 |
$1.90 |
35.10 |
| 2023-06-30 |
70.02 |
$1.99 |
35.19 |
| 2023-03-31 |
67.91 |
$1.52 |
44.68 |
| 2022-12-31 |
65.38 |
$1.07 |
61.10 |
| 2022-09-30 |
52.88 |
$0.67 |
78.93 |
| 2022-06-30 |
63.26 |
$-0.41 |
0.00 |
| 2022-03-31 |
63.52 |
$-0.32 |
0.00 |
| 2021-12-31 |
54.84 |
$0.14 |
391.72 |
| 2021-09-30 |
56.54 |
$0.64 |
88.35 |
| 2021-06-30 |
55.96 |
$1.44 |
38.86 |
| 2021-03-31 |
46.45 |
$1.52 |
30.56 |
| 2020-12-31 |
45.81 |
$1.23 |
37.24 |
| 2020-09-30 |
50.22 |
$0.96 |
52.31 |
| 2020-06-30 |
48.08 |
$0.83 |
57.93 |
| 2020-03-31 |
40.60 |
$0.59 |
68.81 |
| 2019-12-31 |
44.39 |
$0.53 |
83.75 |
| 2019-09-30 |
39.68 |
$0.82 |
48.39 |
| 2019-06-30 |
36.38 |
$0.87 |
41.82 |
| 2019-03-31 |
35.63 |
$0.96 |
37.11 |
| 2018-12-31 |
32.72 |
$0.85 |
38.50 |
| 2018-09-30 |
34.09 |
$0.96 |
35.51 |
| 2018-06-30 |
29.91 |
$1.06 |
28.22 |
| 2018-03-31 |
29.79 |
$1.11 |
26.84 |
| 2017-12-31 |
28.76 |
$1.19 |
24.17 |
| 2017-09-30 |
28.08 |
$1.40 |
20.06 |
| 2017-06-30 |
27.83 |
$1.53 |
18.19 |
| 2017-03-31 |
25.42 |
$1.34 |
18.97 |
| 2016-12-31 |
21.59 |
$1.39 |
15.53 |
| 2016-09-30 |
25.97 |
$0.98 |
26.50 |
| 2016-06-30 |
23.54 |
$0.88 |
26.75 |
| 2016-03-31 |
21.96 |
$1.16 |
18.93 |
| 2015-12-31 |
25.66 |
$1.12 |
22.91 |
| 2015-09-30 |
24.05 |
$0.68 |
35.63 |
| 2015-06-30 |
23.76 |
$0.48 |
50.02 |
| 2015-03-31 |
25.52 |
$0.51 |
50.04 |
| 2014-12-31 |
25.53 |
$0.49 |
52.10 |
| 2014-09-30 |
25.91 |
$0.41 |
63.98 |
| 2014-06-30 |
26.61 |
$0.80 |
33.26 |
| 2014-03-31 |
23.23 |
$0.82 |
28.50 |
| 2013-12-31 |
20.66 |
$1.02 |
20.25 |
| 2013-09-30 |
18.07 |
$1.84 |
9.82 |
| 2013-06-30 |
16.17 |
$1.95 |
8.29 |
| 2013-03-31 |
17.09 |
$2.26 |
7.58 |
| 2012-12-31 |
15.52 |
$2.49 |
6.23 |
| 2012-09-30 |
15.71 |
$2.46 |
6.39 |
| 2012-06-30 |
14.41 |
$3.14 |
4.60 |
| 2012-03-31 |
14.33 |
$3.26 |
4.40 |
| 2011-12-31 |
14.29 |
$3.66 |
3.91 |
| 2011-09-30 |
13.70 |
$3.65 |
3.76 |
| 2011-06-30 |
15.17 |
$2.90 |
5.23 |
| 2011-03-31 |
13.97 |
$2.87 |
4.88 |
| 2010-12-31 |
13.47 |
$2.79 |
4.84 |
| 2010-09-30 |
14.79 |
$2.75 |
5.38 |
| 2010-06-30 |
13.56 |
$2.95 |
4.60 |
| 2010-03-31 |
12.87 |
$2.81 |
4.58 |
| 2009-12-31 |
13.01 |
$2.60 |
5.01 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$233.060B |
$45.811B |
|
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
|
